Mouse IL-7-Fc

Mouse IL-7-Fc is a recombinant fusion protein composed of mouse interleukin-7 (IL-7) and the mutated Fc region of human IgG1.

Mouse IL-7-Fc is specifically designed for in vivo studies using mouse models and provides an extended plasma half-life compared to conventional recombinant IL-7.

Select a quality grade:
Select a size:
Other sizes
Specifications for Mouse IL-7-Fc
Overview

Mouse IL-7-Fc is a recombinant fusion protein composed of mouse interleukin-7 (IL-7) and the mutated Fc region of human IgG1.

Mouse IL-7-Fc is specifically designed for in vivo studies using mouse models and provides an extended plasma half-life compared to conventional recombinant IL-7.

Applications

Mouse IL-7-Fc can be used for a variety of applications including:

  • Investigating immunomodulatory, antitumor and therapeutic effects in in vivo mouse models
  • In vitro expansion and priming of T cells
  • In vitro differentiation of T cells and iNKT cells.

Optimal concentration for a specific application should be determined by a dose-response experiment.

Detailed product information

Biological activity

Determination method
Proliferation of 2E8 cells
Research grade
≥ 5×104 U/mg
Premium grade
≥ 1×105 U/mg
We measure the biological activity of each batch of MACS Premium-Grade Cytokines and state the results in the Certificate of Analysis (CoA). Based on the lot-specific activity, exact doses of active cytokine can be applied to cell culture experiments. This allows for reproducible cell culture conditions without the need for time-consuming lot-to-lot testing.
Background information

Mouse IL-7-Fc (Fc-fused Mouse IL-7) is a fusion protein consisting of recombinant Mouse IL-7 and the mutated Fc region of human IgG1. The Fc region contains mutations that prevent binding to Fc gamma receptors. Due to the Fc domain forming stable homodimers, the fusion protein presents two IL-7 molecules, one on each Fc arm, resulting in a dimeric configuration of IL-7.

In its function as a stimulatory cytokine, IL-7 is crucial for the development, differentiation and maintenance of T and B cells, and has shown therapeutic potential in boosting immune and antitumor responses. However, IL-7 has a short half-life in vivo and can only act in an autocrine or paracrine manner over short distances. Fusion to the dimeric Fc region extends the protein's half-life in the bloodstream by reducing its clearance rate. While mutations in the Fc region prevent it from binding to Fc gamma receptors (FcγRs), the Fc region can interact with neonatal Fc receptor (FcRn), which protects the protein from degradation and facilitates transcytosis. This results in prolonged circulation time and better tissue distribution, making IL-7-Fc a promising candidate for therapeutic applications [1, 2].

In mice, the administration of Fc-fused IL-7 proteins has been shown to mobilize hematopoietic stem and progenitor cells from the bone marrow [3], enhance anti-tumor effects in cancer immunotherapy by promoting the expansion of CD8+ cells and have protective effects against viral infections [4, 5]. Additionally, the recombinant protein efineptakin alfa (NT-17), another Fc-fused IL-7 variant, has been shown to enhance the expansion, persistence and anti-tumor efficacy of CAR T cells in mice, including in the treatment of solid tumors [6, 7].

Mouse IL-7-Fc can be used for in vivo studies in mouse models of disease. The recombinant protein is produced in a human embryonic kidney (HEK) cell line, to ensure proper folding and post-translational modifications.

Product data and images for Mouse IL-7-Fc
Figure 1

SDS-PAGE of Mouse IL-7-Fc under reducing (R) and non-reducing (NR) conditions.

Figure 2

Mouse IL-7-Fc activity assay. The biological activity of Mouse IL-7-Fc, premium grade was determined by proliferation assay using mouse 2E8 cells.

Resources for Mouse IL-7-Fc
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for Mouse IL-7-Fc
Publications
  1. Kim, M.Y. et al. (2022) A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity. Nat Commun 13 (1): 3296
  2. Li, D. et al. (2024) rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors. J Immunother Cancer 12 (7): e008989
  3. Ko, S. et al. (2025) Engineering FcRn binding kinetics dramatically extends antibody serum half-life and enhances therapeutic potential. J Biol Eng. 19 (1): 35
  4. Kim, A. et al. (2024) Understanding the pharmacokinetic journey of Fc-fusion protein, rhIL-7-hyFc using complementary approach of two analytical methods, accelerator mass spectrometry and ELISA. Antib Ther. 7 (2): 105-113
  5. Kwon, D. et al. (2024) Fc-fused IL-7 provides broad antiviral effects against respiratory virus infections through IL-17A-producing pulmonary innate-like T cells. Cell Rep Med. 5 (1): 101362
  6. Kim, S. et al. (2021) Fc-fused IL-7 mobilizes long-term HSCs in a pro-B cell-dependent manner and synergizes with G-CSF and AMD3100. Leukemia 35 (10): 3030-3034
  7. Kang, M.C. et al. (2015) Intranasal Introduction of Fc-Fused Interleukin-7 Provides Long-Lasting Prophylaxis against Lethal Influenza Virus Infection. J Virol. 90 (5): 2273-2284

You have previously chosen International as your location.
What do you want to do?